Developing Story: From CLEOPATRA to Life on Enhertu – HER2+ MBC with Dr. Erika Hamilton & Dr. Sarah Premji
wenty-five years ago, HER2-positive breast cancer meant a two-year death sentence. Today, patients are living 12+ years on first-line treatment—and some are being cured.
In this deep dive, host Victoria Goldberg (living with metastatic HER2+ cancer for 12 years) and leading oncologists Dr. Erika Hamilton and Dr. Sarah Premji unpack the drugs, trials, and real-world strategies transforming one of cancer's most feared diagnoses into its greatest success story.
From CLEOPATRA's game-changing 16-month survival boost to antibody-drug conjugates that deliver chemotherapy straight to cancer cells, learn how precision medicine is rewriting the rules—and what patients need to know about side effects, sequencing, and hope.
Developing Story: Triple Negative MBC - Hard Truths, Real Hope with Dr Sarah Premji
Triple negative metastatic breast cancer has long been considered the hardest subtype to treat. That is changing and faster than most patients realize. Dr. Sarah Premji joins Victoria Goldberg to break down two landmark FDA approvals, the science behind antibody-drug conjugates, and what's coming next in the pipeline
Developing Story: Beyond Camizestrant — The Evolving Landscape of ER+/HER2- MBC with Dr. Sarah Premji
The oral SERD era has arrived, and the treatment landscape for HR+/HER2- metastatic breast cancer is changing fast. Hosts Victoria Goldberg and Abigail Johnston sit down with Dr. Sarah Premji of Sarah Cannon to map out what has shifted beyond SERENA-6, from new FDA approvals and emerging mechanisms to real-world sequencing decisions and the latest trial data. If you are trying to make sense of a rapidly evolving algorithm, this episode is for you.